BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $378.43 Consensus Target Price from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $378.4286.

Several brokerages have weighed in on ONC. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price objective on the stock in a report on Monday, January 12th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Finally, Citigroup upped their price target on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $337.79 on Friday. The firm has a market cap of $37.04 billion, a PE ratio of 662.33 and a beta of 0.47. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. BeOne Medicines has a 52 week low of $196.45 and a 52 week high of $385.22. The business’s fifty day simple moving average is $327.61 and its 200-day simple moving average is $321.11.

Insider Activity

In related news, SVP Chan Henry Lee sold 996 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $349.17, for a total transaction of $347,773.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Xiaobin Wu sold 10,000 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $356.02, for a total value of $3,560,200.00. Following the completion of the transaction, the chief operating officer directly owned 6,009 shares in the company, valued at $2,139,324.18. This trade represents a 62.46% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 128,610 shares of company stock worth $41,114,068. Insiders own 6.62% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Primecap Management Co. CA purchased a new stake in BeOne Medicines in the second quarter valued at $1,231,720,000. Capital International Investors increased its position in shares of BeOne Medicines by 3.3% during the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after purchasing an additional 161,052 shares in the last quarter. Temasek Holdings Private Ltd purchased a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $244,603,000. Marshall Wace LLP acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $113,190,000. Finally, Bank of America Corp DE boosted its position in shares of BeOne Medicines by 23.5% in the 3rd quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock valued at $117,629,000 after purchasing an additional 65,763 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.